Summary
The submitted statements are largely generic and do not align with the provided FDA label context for FAVLYXA (fluorouracil injection). Numerous claims are unsupported by the supplied prescribing information and appear to concern topical fluorouracil and pricing/insurance, which are not supported by the label text provided.
Category Scores
Accurate Statements
Patients with complete DPD deficiency (DPYD variants causing complete/near complete absence of DPD activity) are at increased risk for acute early-onset serious toxicity including potentially fatal adverse reactions from fluorouracil (FAVLYXA).
Sections 5.1 and 12.5 of FAVLYXA label: increased risk of acute early-onset toxicity and serious, including fatal adverse reactions in homozygous/compound heterozygous DPYD variants resulting in complete DPD deficiency.
Unsupported Statements
Fluorouracil cream is a topical medication used to treat certain skin conditions.
The provided FDA label excerpts are for FAVLYXA (fluorouracil) Injection, USP, and do not support claims about a topical cream or its labeled indications.
Fluorouracil cream is commonly prescribed for actinic keratoses.
No labeling text for topical fluorouracil/cream indications (e.g., actinic keratoses) was provided in the supplied label excerpts.
Actinic keratoses are precancerous skin lesions caused by prolonged sun exposure.
The provided label excerpts do not include this definition/pathophysiology.
Fluorouracil cream is used for superficial basal cell carcinomas.
No labeling text supporting this use/indication for topical fluorouracil/cream was provided.
Fluorouracil cream works by inhibiting DNA synthesis in rapidly dividing cells.
The provided label excerpts do not describe mechanism of action in this way.
Fluorouracil cream causes cancerous or precancerous cells to die.
Not supported by the provided label excerpts.
Without insurance, the cost of fluorouracil cream can range from approximately $20 to over $100 for a standard tube.
The supplied prescribing information excerpts do not include pricing information.
A 2.5% fluorouracil cream in a 25-gram tube might cost around $40 to $60 at a retail pharmacy.
The supplied prescribing information excerpts do not include product-specific retail pricing.
Fluorouracil cream price varies by specific formulation, dosage strength, quantity, pharmacy, insurance coverage, and whether it is generic or brand-name.
No pricing/market-access information is present in the provided label excerpts.
Price is influenced by concentration of fluorouracil (e.g., 0.5%, 2%, 5%).
No pricing information is present in the provided label excerpts.
Price is influenced by tube size (e.g., 25g, 40g).
No pricing information is present in the provided label excerpts.
Generic versions of fluorouracil cream are generally less expensive than brand-name formulations.
No pricing comparison information is present in the provided label excerpts.
Most insurance plans provide coverage for fluorouracil cream, particularly when prescribed for medically necessary treatments like actinic keratoses or basal cell carcinoma.
No insurance coverage or payer policy statements are present in the provided label excerpts.
Out-of-pocket cost depends on insurance plan deductibles, copayments, and coinsurance.
No cost-sharing/payer guidance is present in the provided label excerpts.
Generic versions of fluorouracil cream are widely available.
No availability/market distribution information is present in the provided label excerpts.
Pharmaceutical discount cards or coupons can reduce out-of-pocket expense for fluorouracil cream.
No statements about discount cards/coupons are present in the provided label excerpts.
Some manufacturers offer patient assistance programs that may provide financial help for eligible individuals.
No patient assistance statements are present in the provided label excerpts.
Comparing prices across different pharmacies, including local ones and online options, can lead to significant savings for fluorouracil cream.
No pharmacy price comparison guidance is present in the provided label excerpts.
Both generic and brand-name fluorouracil creams contain the same active ingredient, fluorouracil.
The provided label excerpts do not address generic vs brand-name equivalence for topical fluorouracil creams.
Generic and brand-name fluorouracil creams are required to meet the same safety and efficacy standards set by regulatory agencies like the U.S. Food and Drug Administration (FDA).
This regulatory generalization is not supported by the provided label excerpts.
Generic versions are bioequivalent to their brand-name counterparts.
No bioequivalence statement for fluorouracil creams is present in the provided label excerpts.
Generic versions are typically sold at a lower price than brand-name versions.
No pricing statements are present in the provided label excerpts.
Brand-name fluorouracil creams might be produced by companies like Valeant Pharmaceuticals (now Bausch Health) under names such as Efudex.
No company/product brand-name manufacturing statements are present in the provided label excerpts.
Generic versions of fluorouracil cream are produced by numerous pharmaceutical manufacturers.
No manufacturer listing information is present in the provided label excerpts.
Several pharmaceutical companies manufacture both brand-name and generic versions of fluorouracil cream.
No manufacturer listing information is present in the provided label excerpts.
Contradictions
Important Omissions
Key label-based administration, dosage, contraindications, boxed warnings, and detailed warnings/precautions for FAVLYXA beyond the DPD deficiency excerpts (e.g., full dosing strategy, dose modifications, and contraindication language).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only FDA-label-supported safety claim provided relates to DPD deficiency increasing risk of serious/fatal toxicity with FAVLYXA; however, most other statements are unrelated to the supplied label text (topical use and pricing/insurance), so they do not directly increase risk based on on-label safety instructions contained in the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are about topical fluorouracil creams and pricing/insurance, while the provided FDA label excerpts are for FAVLYXA (fluorouracil) injection; these claims are not supported by the supplied prescribing information.
Suggested Improvement
Restrict statements to what is supported by the provided FAVLYXA label excerpts (e.g., DPD/DPYD testing and avoidance/modification guidance for complete DPD deficiency), and remove unsupported topical, pricing, and generic/brand regulatory/generalization claims unless the relevant label text is provided.